TheraCryf (FRA:8EV) Additional Paid-In Capital : €32.32 Mil(As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Additional Paid-In Capital?

TheraCryf's quarterly additional paid-in capital declined from Sep. 2022 (€31.88 Mil) to Mar. 2023 (€31.59 Mil) but then increased from Mar. 2023 (€31.59 Mil) to Sep. 2023 (€32.32 Mil).

TheraCryf's annual additional paid-in capital increased from Mar. 2021 (€32.47 Mil) to Mar. 2022 (€33.34 Mil) but then declined from Mar. 2022 (€33.34 Mil) to Mar. 2023 (€31.59 Mil).

TheraCryf Additional Paid-In Capital Historical Data

The historical data trend for TheraCryf's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Additional Paid-In Capital Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Additional Paid-In Capital

Get a 7-Day Free Trial

15.44

19.97

32.47

33.34

31.59

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial															32.54	33.34	31.88	31.59	32.32

TheraCryf Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

TheraCryf Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of TheraCryf's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf (FRA:8EV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

EVG:UK

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines